Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HEPARIN AFTER ACUTE MYOCARDIAL-INFARCTION
Autore:
COMMERFORD PJ;
Indirizzi:
GROOTE SCHUUR HOSP,DEPT MED,CARDIAC CLIN,E25 ZA-7925 CAPE TOWN SOUTH AFRICA UNIV CAPE TOWN ZA-7925 CAPE TOWN SOUTH AFRICA
Titolo Testata:
Cardiovascular drugs and therapy
fascicolo: 2, volume: 11, anno: 1997,
pagine: 101 - 109
SICI:
0920-3206(1997)11:2<101:HAAM>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEFT-VENTRICULAR THROMBUS; ACUTE CORONARY SYNDROMES; THROMBOLYTIC THERAPY; UNSTABLE ANGINA; ARTERY DISEASE; STROKE; DISCONTINUATION; PATHOGENESIS; REACTIVATION; REOCCLUSION;
Keywords:
HEPARIN; ACUTE MYOCARDIAL INFARCTION; EMBOLISM HEMORRHAGE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
44
Recensione:
Indirizzi per estratti:
Citazione:
P.J. Commerford, "HEPARIN AFTER ACUTE MYOCARDIAL-INFARCTION", Cardiovascular drugs and therapy, 11(2), 1997, pp. 101-109

Abstract

Heparin is commonly, but by no means universally, used after acute myocardial infarction. When used the dose, route of administration, and duration of therapy varies considerably. The role of heparin is reviewed with particular reference to its use in conjunction with other commonly used therapies, such as aspirin and thrombolytic agents. Intravenous heparin after thrombolytic therapy remains untested in patients treated with aspirin. When used, benefit is seen in a narrow aPTT range,and there have been unexpected increases in mortality in patients with the greatest heparin effect. The addition of delayed subcutaneous heparin to aspirin and thrombolytic therapy does not provide a mortalitybenefit. In patients not treated with thrombolysis, there is no clearevidence that heparin confers significant mortality benefit if patients are treated with aspirin. Heparin therapy may reduce,the incidence of intraventricular thrombus after anterior wall infarction, but thereis no clear evidence that it reduces the clinically important sequelae of cerebral embolism and stroke. Given concerns about increased hemorrhagic rates with heparin and unknown benefit, it is reasonable to conclude that its role in the management of patients with acute myocardial infarction remains unclear.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 01:31:57